Genetic-hormonal pathways to non-squamous lung cancer: prognosticator and a therapeutic target

Research Article

American Journal of BioMedicine
Volume 11, Issue 2, Pages 57-64 | http://dx.doi.org/10.18081/2333-5106/2023.11/57

Mustafa A. Jaber, Kamel F. Al-Salmi, Yousif S. Hamid ^1*

*Correspondence author e-mail: yousifhamid33@gmail.com: ¹ Genetic Department, Medical School, Cario.

Received 12 January 2023 Revised 13 March 2023 Accepted 21 March 2023 Published 11 April 2023

Abstract

Lung carcinoma is one of the most commonly diagnosed cancers worldwide, and the leading cause of cancer deaths across the globe. The most recent epidemiological data indicate that lung cancer is attributed to 1 in 10 (11.4%) cancers diagnosed, and 1 in 5 (18.0%) deaths worldwide. Estrogen is speculated to play an important role in lung carcinogenesis. This review data indicates a significant role of the female sex hormone β-estradiol in the etiopathogenesis, clinical treatment, and prognosis of non-squamous lung cancer (NSCLC). Estrogen activity in the growth of NSCLC tumors has been confirmed by a number of studies, and lowering the level of estrogen hormones could have a positive effect on antitumor activity in this area.

Keywords:Non-squamous lung cancer; Estrogen; β-estradiol; Lung cancer survival

Copyright: © 2023 Hamid YS et al. This article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Cited by other articlesReferencesDownload this articleStatistics

The citation data is computed by the following citation measuring services:

1. American Cancer Society. Key statistics for lung cancer. Available from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html

2. Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg 2013; 61:254-261. https://doi.org/10.1007/s11748-012-0180-6

3. Cancer.Net. Lung Cancer-Non-Small Cell: Statistics: ASCO; 2020 [updated 5/202012/31/20]. Available from: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics.

4. Huang J, Reckamp KL. Immunotherapy in Advanced Lung Cancer. Oncology (Williston Park) 2020; 34(7):272-9. https://doi.org/10.46883/ONC.2020.3407.0272

5. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 373(2):123-35. https://doi.org/10.1056/NEJMoa1504627

6. Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer 2017; 17(1):882. https://doi.org/10.1186/s12885-017-3893-1

7. Nakaya A, Kurata T, Yoshioka H, Takeyasu Y, Niki M, Kibata K, et al. Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab. Int J Clin Oncol 2018; 23(4):634-40. https://doi.org/10.1007/s10147-018-1250-2

8. Chang CH, Hsiao CF, Yeh YM, Chang GC, Tsai YH, Chen YM, et al. Circulating interleukin-6 level is a prognostic marker for survival in advanced nonsmall cell lung cancer patients treated with chemotherapy. Int J Cancer 2013; 132(9):1977-85. https://doi.org/10.1002/ijc.27892

9. Xie M, You S, Chen Q, et al. Progesterone inhibits the migration and invasion of A549 lung cancer cells through membrane progesterone receptor a-mediated mechanisms. Oncol Rep 2013; 29:1873-80. https://doi.org/10.3892/or.2013.2336

10. Egloff AM, Rothstein ME, Seethala R, et al. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res 2009; 15(21):6529-40. https://doi.org/10.1158/1078-0432.CCR-09-0862

11. Urman A., Hosgood D. Lung Cancer Risk, Genetic Variation, and Air Pollution. EBioMedicine 2015; 2:491-492. https://doi.org/10.1016/j.ebiom.2015.05.007

12. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA A Cancer J Clin 2021; 71:7-33. https://doi.org/10.3322/caac.21654

13. Peng J, Meireles SI, Xu X, et al. Estrogen metabolism in the human lung: impact of tumorigenesis, smoke, sex and race/ethnicity. Oncotarget 2017; 8:106778-89. https://doi.org/10.18632/oncotarget.22269

14. Wakelee HA, Wang W, Schiller JH, Langer CJ, Sandler AB, Belani CP, Johnson DH, Group ECO. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 2006; 1:441-6. https://doi.org/10.1097/01243894-200606000-00011

15. Kiyohara C, Ohno Y. Sex differences in lung cancer susceptibility: a review. Gend Med 2010; 7:381-401. https://doi.org/10.1016/j.genm.2010.10.002

16. Hsu LH, Liu KJ, Tsai MF, et al. Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Sci 2015; 106:51-59. https://doi.org/10.1111/cas.12558

17. Stabile LP, Siegfried JM. Estrogen receptor pathways in lung cancer. Curr. Oncol. Rep. 2004; 6:259-267. https://doi.org/10.1007/s11912-004-0033-2

18. Schwartz AG, Prysak GM, Murphy V, Lonardo F, Pass H, Schwartz J, Brooks S. Nuclear estrogen receptor beta in lung cancer: Expression and survival differences by sex. Clin. Cancer Res 2005; 11:7280-7287. https://doi.org/10.1158/1078-0432.CCR-05-0498

19. Liu Y, Inoue M, Sobue T, Tsugane S. Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: A large-scale population-based cohort study. Int. J. Cancer 2005; 117:662-666. https://doi.org/10.1002/ijc.21229

20. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin. Cancer Res 2008; 14:4417-4426. https://doi.org/10.1158/1078-0432.CCR-07-1950

21. Hsu LH, Feng AC, Kao SH, et al. Second primary lung cancers among breast cancer patients treated with anti-estrogens have a longer cancer-specific survival. Anticancer Res 2015; 35:1121-1127.

22. Kawai H. Estrogen receptors as the novel therapeutic biomarker in non-small cell lung cancer. World J. Clin. Oncol 2014; 5:1020-1027. https://doi.org/10.5306/wjco.v5.i5.1020

23. Zhang G, Liu X, Farkas AM, Parwani AV, et al. Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. Mol. Endocrinol 2009; 23:146-156. https://doi.org/10.1210/me.2008-0431

24. Mohammed KG, Mohammed SM, Hadi NR, et al. Association between Natural Killer Cell Cytotoxicity and the Progression of Non-Small Cell Lung Cancer. Sys Rev Pharm 2020; 11(4):543-551. https://doi.org/10.31838/srp.2020.4.81

25. Mah V, Seligson DB, Li A, et al. Aromatase expression predicts survival in women with early-stage non-small cell lung cancer. Cancer Res 2007; 67(21):10484-10490. https://doi.org/10.1158/0008-5472.CAN-07-2607

26. Yousif NG. Fibronectin promotes migration and invasion of ovarian cancer cells through up‐regulation of FAK-PI 3 K/A kt pathway. Cell biology international 2014; 38(1): 85-91. https://doi.org/10.1002/cbin.10184

27. Kohno M, Okamoto T, Suda K, et al. Prognostic and therapeutic implications of aromatase expression in lung adenocarcinomas with EGFR mutations. Clin Cancer Res 2014; 20(13):3613-3622. https://doi.org/10.1158/1078-0432.CCR-13-2683

28. Tang H, Liao Y, Chen G, et al. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β Med Oncol 2012; 29(4):2640-2648. https://doi.org/10.1007/s12032-012-0198-8

29. Garon EB, Siegfried JM, Dubinett SM, et al. Results of TORIL-03, a randomized, multicenter phase Ⅱ clinical trial of erlotinib (E) or E + fulvestrant (F) in previously treated advanced non-small cell lung cancer NSCLC. In: Procceding of the 104th Annual Meeting of the American Association for Cancer Research, 2013 Apr 6-10, Washington DC. Philadelphia (PA): AACR. 2013, Abstract 4664. https://doi.org/10.1158/1538-7445.AM2013-4664

30. Schumann C. Differences in the survival rate between premenopausal and postmenopausal women with lung cancer: US SEER database. American Journal of BioMedicine 2014; 2(4): 270-276. https://doi.org/10.18081/2333-5106/014-04/270-276

31. Garon EB, Pietras RJ, Finn RS, et al. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small cell lung cancer. J Thoracic Oncol 2013; 8(3):270-278. https://doi.org/10.1097/JTO.0b013e31827d525c

32. Nose N, Uramoto H, Iwata T, et al. Expression of estrogen receptor beta predicts a clinical response and longer progression-free survival after treatment with EGFR-TKI for adenocarcinoma of the lung. Lung Cancer 2011; 71(3):350-355. https://doi.org/10.1016/j.lungcan.2010.06.009

33. Chen XQ, Zheng LX, Li ZY, et al. Clinicopathological significance of oestrogen receptor expression in non-small cell lung cancer. J Int Med Res 2017; 45(1):51-58. https://doi.org/10.1177/0300060516666229

34. Raso MG, Behrens C, Herynk MH, et al. Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res 2009; 15(17):5359-5368. https://doi.org/10.1158/1078-0432.CCR-09-0033

35. Deng F, Li M, Shan WL, et al. Correlation between epidermal growth factor receptor mutations and the expression of estrogen receptor-β in advanced non-small cell lung cancer. Oncol Lett 2017; 13(4):2359-2365. https://doi.org/10.3892/ol.2017.5711

36. Hsu LH, Liu KJ, Tsai MF, et al. Estrogen adversely affects the prognosis of patients with lung adenocarcinoma. Cancer Sci 2015; 106(1):51-59. https://doi.org/10.1111/cas.12558

37. Bouchardy C, Benhamou S, Schaffar R, et al. Lung cancer mortality risk among breast cancer patients treated with anti-estrogens. Cancer 2011; 117:1288-1295. https://doi.org/10.1002/cncr.25638

38. Liu W, Konduri SD, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem 2006; 281(15):9837-9840. https://doi.org/10.1074/jbc.C600001200

39. Niikawa H, Suzuki T, Miki Y, et al. Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma. Clin Cancer Res 2008; 14(14):4417-4426. https://doi.org/10.1158/1078-0432.CCR-07-1950

40. Wang Y, Huang D, Xu WY, et al. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in non-small cell lung cancer: a meta-analysis. Oncol Res Treat 2019; 42: 523-531. https://doi.org/10.1159/000501726

1. Access through OpenAthens

2. PDF XML

For any technique error please contact us.

Downloads: 104

APA

Chandra, S., and Vijayakumar, V. (2023). Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors. American Journal of BioMedicine, 11(1), 10-21.doi: 10.18081/2333-5106/2023.11/10

MLA

Sambit Chandra; Sujeet D. Vijayakumar. “Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors”. American Journal of BioMedicine, 11, 1, 2023, 10-21. doi: 10.18081/2333-5106/2023.11/10

HARVARD

Chandra, S., Vijayakumar, V. (2023). Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors. American Journal of BioMedicine, 11(1), PP. 10-21.doi: 10.18081/2333-5106/2023.11/10

VANCOUVER

Chandra, S., Vijayakumar, V. Laparoscopic ovarian electrocauterization in polycystic ovarian syndrome: outcome and Influencing factors. American Journal of BioMedicine, 2023; 11(1):10-21.doi: 10.18081/2333-5106/2023.11/10